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The intracellular accumulation of norfloxacin and pefloxacin in Klebsiella pneumoniae was evaluated. The
roles of lipopolysaccharide, capsule, and outer membrane proteins were not important for the intrabacterial
accumulation of fluoroquinolones in isogenic strains with known outer membrane alterations. In fluoroquin-
olone-resistant clinical isolates also expressing GyrA alterations, an active efflux leading to decreased accu-
mulation of the drugs enhanced their resistance to these agents.
Several mechanisms are involved in the resistance to fluo-
roquinolones (FQ) by gram-negative bacteria. In Escherichia
coli, point mutations in the quinolone resistance-determining
region (QRDR) of gyrA (21) are the most important cause of
resistance. Mutations in gyrB are uncommon in clinical isolates
(22), while mutations in parC (19) or (much less frequently) in
parE (4) contribute to increased levels of resistance. The gyrA
gene of Klebsiella pneumoniae has been cloned and sequenced
and is similar (about 85% at the nucleotide level and about
90% at the amino acid level) to its E. coli homolog (5). The
role of gyrA mutations in FQ-resistant K. pneumoniae has been
demonstrated, these mutations being analogous to those pre-
viously observed in E. coli (6, 7). Decreased activity of FQ
against E. coli has also been related to a reduced intracellular
drug accumulation due to lipopolysaccharide or porin alter-
ations impairing uptake or because of enhanced efflux (10, 11).
Cross-resistance between FQ and beta-lactams in K. pneu-
moniae mutants has been related to outer membrane protein
alterations (12, 17). Expression of the ramA locus from K.
pneumoniae in E. coli confers resistance to norfloxacin, deter-
mines the active efflux of tetracycline and chloramphenicol,
and causes almost complete loss of OmpF (8). It has been
reported that the high hydrophobicity of FQ is generally asso-
ciated with decreased accumulation in both E. coli and Pseudo-
monas aeruginosa (14). The lipopolysaccharide of the outer
leaflet of the outer membrane in some bacteria blocks the
access of the drug to the microorganism. Other reports indi-
cate that hydrophylic compounds may cross the outer mem-
brane through porins (11).
The objectives of this study were to evaluate the accumula-
tion of two FQ with different hydrophobicities (norfloxacin
[NFX] and pefloxacin [PFX]) in K. pneumoniae by studying
FQ-susceptible isogenic strains with known outer membrane
alterations and FQ-resistant clinical isolates.
(This work was presented in part at the 36th Interscience
Conference on Antimicrobial Agents and Chemotherapy, New
Orleans, La., 15 to 18 September 1996 [13].)
An environmental isolate, K. pneumoniae C3 (18), and the
derived mutants KT717, KT793, and KT5003 (1–3, 9) were
used. K. pneumoniae LB2 and LB4 (12) and K. pneumoniae
CSUB10S and CSUB10R (kindly provided by J. Liñares [Bar-
celona, Spain]) are clinical isolates; LB and CSUB isolates are
epidemiologically unrelated, as determined by pulse-field gel
electrophoresis (data not shown). The outer membrane char-
acteristics of all strains are shown in Table 1. MICs of NFX
(Sigma, Madrid, Spain) and PFX (Rhône-Poulenc, Antony,
France) were determined by microdilution, according to Na-
tional Committee for Clinical Laboratory Standards NCCLS
guidelines (16). To assess FQ accumulation in K. pneumoniae
C3, bacterial cells were incubated with 2, 5, 10, or 50 mg of each
FQ per ml at 37°C for different periods of time. For the other
strains a concentration of 10 mg/ml was used. The cells were
separated from the extracellular solution by centrifugation
through a silicon oil barrier (1.029 g/cm3). The entire cell pellet
was placed in 2 ml of 0.1 M glycine-HCl buffer (pH 3.0),
vortexed, and centrifuged for 5 min at 12,800 3 g. The amount
of FQ in the supernatant was determined by spectrofluorom-
etry. Bacterially associated FQ was expressed as nanograms of
FQ per milligram [dry weight] of cells. The effects of the
energy inhibitors carbonyl cyanide m-chlorophenylhydrazone
(CCCP) (0.1 mM; Sigma) and 2,4-dinitrophenol (Sigma) were
also evaluated. Data are expressed as means 6 standard devi-
ations. Differences among groups were compared by analysis
of variance, which was used to assess statistical significance at
P values of #0.05.
To analyze alterations in the GyrA subunit of DNA gyrase
and the ParC subunit of topoisomerase IV, the QRDR of gyrA
and the analogous region of parC were sequenced with previ-
ously described primers (6). MICs of PFX were identical for K.
pneumoniae C3 and the derived mutants. A two-dilution step
increase in the MIC of NFX for mutant KT5003 was observed
in comparison with the parental strain K. pneumoniae C3.
MICs of both quinolones for K. pneumoniae LB4 and
CSUB10R were higher than for K. pneumoniae LB2 and
CSUB10S, respectively (Table 1). The intracellular accumula-
tion of NFX and PFX in K. pneumoniae C3 was rapid (Fig. 1)
and not saturable at extracellular concentrations ranging from
2 to 50 mg/ml. Nonsignificant differences in the accumulation
of FQ were observed in isogenic strains KT717, KT793, and
KT5003. These results indicate that the roles of cell wall com-
ponents in the intrabacterial accumulation of FQ with different
grades of hydrophobicity are small or nonexistent. The high
susceptibilities of the nonclinical strains, K. pneumoniae C3
and the mutants, to FQ are probably related to the absence of
specific mechanisms of resistance to FQ. The accumulations of
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both FQ were significantly lower in the clinical K. pneumoniae
isolates LB4 and CSUB10R. Preincubation of strains in the
presence of CCCP did not modify the accumulation of NFX in
K. pneumoniae C3, but it significantly increased the accumula-
tion of NFX in both K. pneumoniae LB4 and CSUB10R (Table
1). Similar results were obtained with 2,4-dinitrophenol. This
suggests that, at least in part, the reduced accumulation ob-
served in both clinical isolates could be caused by an energy-
dependent mechanism that pumps FQ out of the bacterial cell.
Deguchi et al. have also described an active efflux system for
NFX in FQ-resistant K. pneumoniae (7).
Different authors have found discrepant amino acids at po-
sition 83 of the GyrA protein in FQ-susceptible K. pneumoniae:
Thr (accession no. X16817 [5] and strain C3 [this work]) and
Ser (ATCC 13833 [6]). In either case, a change in this position
was observed in FQ-resistant strains LB2-LB4 (Tyr) and
CSUB10S-CSUB10R (Phe). Both pairs of strains also have
changes at position 112 (Val to Ile). These changes should
contribute to the observed resistance to FQ, as similar changes
have been observed in other gram-negative organisms (6, 20,
21). No changes in the QRDRs of the parC genes of the four
clinical isolates studied were observed, in comparison with the
sequence for K. pneumoniae C3. New studies are in progress to
elucidate the roles of porin deficiency, efflux, and topoisomer-
ase modification in the resistance of K. pneumoniae to FQ.
Deguchi et al. have suggested that the system responsible for
active efflux of NFX may contribute to increased resistance to
beta-lactams, chloramphenicol, and tetracycline. The relative
importance of the efflux systems of K. pneumoniae LB4 and
CSUB10R to antimicrobial agents other than FQ is not known.
Both strains produce broad- and extended-spectrum beta-lac-
tamases. Loss of porins may explain the increased resistance to
beta-lactams in comparison with their respective parental
strains LB2 and CSUB10S (12), but this does not discount the
importance of the efflux mechanism as a contributor to beta-
lactam resistance in K. pneumoniae, as has previously been
shown for P. aeruginosa (15). As soon as the genetics of the
efflux mechanisms in these two strains are determined, their
importance as factors contributing to resistance to antimicro-
bial agents other than FQ can be defined.
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TABLE 1. Susceptibilities to and accumulation of NFX in four isogenic and four clinical K. pneumoniae strains
Strain





O-Ag K-Ag OmpK34 OmpK35 OmpK36 Control CCCP
Isogenic strains
C3 O1 K66 1 1 1 0.015 366 6 65 346 6 46
KT717 O1 2 1 1 1 0.03 330 6 67 ND
KT793 2 2 1 1 1 0.03 299 6 68 ND
KT5003 2 2 1 2 2 0.06 314 6 54 ND
Clinical strains
LB2 ND ND 1 1 2 2 286 6 24 385 6 65
LB4 ND ND 1 2 2 4 116 6 21 263 6 38
CSUB10S ND ND 1 1 2 4 313 6 6 ND
CSUB10R ND ND 1 2 2 16 66 6 20 76 6 9
a OmpK34, OmpK35, and OmpK36 are the K. pneumoniae homologs of E. coli OmpA and porins OmpF and OmpC, respectively. O-Ag, O antigen; K-Ag, K antigen;
ND, not determined.
b Data are means 6 standard deviations of five experiments.
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Volume 42, no. 7, p. 1850–1852, 1998. Page 1851, Table 1: “76 6 9” for accumulation of NFX after CCCP treatment for strain
CSUB10R should read “161 6 18.”
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